Effect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy - LOMCAD

Ohara Tomoyuki0 个研究点目标入组 20 人开始时间: 2022年8月9日最近更新: 2024年4月1日

试验速览

暂无简介。

•Patients meeting all of the following criteria will be included
•1) Patients diagnosed with CADASIL by genetic testing
•2) Patients with symptomatic cerebral infarction, transient ischemic attack, or asymptomatic MRI diffusion-weighted imaging (DWI) detection of acute ischemic lesions within 6 months prior to obtaining consent, and once or more within 2 years prior to the most recent symptomatic cerebral infarction, transient ischemic attack, or asymptomatic head MRI DWI detection of acute ischemic foci .
•3) Patients who are between 20 and 70 years of age at the time of consent
•4) Patients who have obtained written consent from the patient or a surrogate to participate in the clinical trial.

•Patients who fall into any of the following categories will not be included in this study
•1) Patients who have taken lomerizine hydrochloride for more than 1 month continuously within 1 year prior to enrollment
•2) Patients with a history of hypersensitivity to lomerizine hydrochloride
•3) Patients with a history of symptomatic intracranial hemorrhage
•4) Patients who are unable to discontinue acetazolamide medication
•5) Patients on concomitant antiplatelet and anticoagulant medications or taking two or more antiplatelet medications at the time of enrollment
•6) Patients with severe hepatic dysfunction at the time of enrollment
•7) Women who wish to become pregnant during the study period, are pregnant, may become pregnant, or are breastfeeding at the time of consent
•8) Patients with a modified Rankin Scale (mRS) of 4 or higher at the time of enrollment
•9) Patients who are unable to undergo MRI examinations (claustrophobia, metal in the body, etc.)
•10) Patients who cannot have a baseline MRI examination at the study site within 42 days prior to enrollment
•11) Patients who are participating in another clinical trial at the time of consent
•12) Other patients who are deemed by the investigator to be inappropriate to participate in the clinical trial.

发起方

Ohara Tomoyuki